Demographic Variation In US Outpatient Hydroxychloroquine And Ivermectin Use During The COVID-19 Pandemic

被引:0
作者
Rockwell, Michelle S. [1 ]
Vangala, Sitaram [2 ]
Hadfield, Michael [3 ]
Cantor, Jonathan [4 ]
Skinner, Dale [3 ]
Craff, Melody [3 ]
Fendrick, A. Mark [5 ]
Damberg, Cheryl L. [4 ]
Kahn, Katherine [2 ,4 ]
Mafi, John N. [2 ,4 ]
机构
[1] Virginia Polytech Inst & State Univ, Roanoke, VA 24016 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Milliman MedInsight, Seattle, WA USA
[4] RAND Corp, Santa Monica, CA USA
[5] Univ Michigan, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
LEVEL SOCIAL VULNERABILITY; ORAL ANTIVIRAL DRUGS; UNITED-STATES; DECEMBER; 23; TRENDS; PATTERNS;
D O I
10.1377/hlthaff.2024.00452
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
As COVID-19 surged across the US starting in 2020, so too did the use of repurposed medications such as hydroxychloroquine and ivermectin to treat COVID-19 infections. Use of these medications throughout the public health emergency and across demographic subgroups is not well understood. Using insurance claims from the MedInsight Emerging Experience Research Database for 8.1 million patients from all fifty US states, we evaluated COVID-19-associated outpatient hydroxychloroquine and ivermectin use and spending throughout the public health emergency (January 30, 2020-May 11, 2023) versus pre-public health emergency rates. Extrapolated to the US population, approximately three million prescriptions (totaling $272 million in spending) were used; 7 percent followed Food and Drug Administration authorization of outpatient COVID-19 medications ritonavir-boosted nirmatrelvir, molnupiravir, and remdesivir in December 2021 and January 2022. The combined overall hydroxychloroquine and ivermectin utilization rate was threefold higher in older versus younger adults. Ivermectin use was greater among patients with the highest versus the lowest degree of social vulnerability and in the southern US versus other regions. These findings can inform policy efforts to mitigate the harms of non-evidence-based care, particularly among vulnerable populations.
引用
收藏
页码:246 / 255
页数:10
相关论文
共 49 条
[1]  
Ally AJ, 2023, Milliman White Paper
[2]  
American Medical Association, 2021, Press release, AMA, APhA, ASHP statement on ending use of ivermectin to treat COVID-19
[3]   Administration of Anti-SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization [J].
Anderson, Timothy S. ;
O'Donoghue, Ashley ;
Mechanic, Oren ;
Dechen, Tenzin ;
Stevens, Jennifer .
JAMA NETWORK OPEN, 2022, 5 (08) :e2228997
[4]  
[Anonymous], 2023, Centers for Disease Control and Prevention
[5]  
[Anonymous], U.S. Bureau of Labor Statistics. (2016). Retrieved from https://www.bls.gov/
[6]  
[Anonymous], 2019, MEDICARE PART DRUG S
[7]  
[Anonymous], US Food and Drug Administration. Guidance for Industry. Considering whether an FDA-regulated product involves the application of nanotechnology. Silver Spring, MD, 2014. Available from URL: http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm (last accessed Jul 26, 2016).
[8]   Association of County-Level Prescriptions for Hydroxychloroquine and Ivermectin With County-Level Political Voting Patterns in the 2020 US Presidential Election [J].
Barnett, Michael L. ;
Gaye, Marema ;
Jena, Anupam B. ;
Mehrotra, Ateev .
JAMA INTERNAL MEDICINE, 2022, 182 (04) :452-454
[9]   Dispensing of Ivermectin From Veterans Administration Pharmacies During the COVID-19 Pandemic [J].
Becker, Nora V. ;
Seelye, Sarah ;
Chua, Kao-Ping ;
Echevarria, Kelly ;
Conti, Rena M. ;
Prescott, Hallie C. .
JAMA NETWORK OPEN, 2023, 6 (02) :E2254859
[10]   Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients [J].
Bhatt, Ankeet S. ;
McElrath, Erin E. ;
Claggett, Brian L. ;
Bhatt, Deepak L. ;
Adler, Dale S. ;
Solomon, Scott D. ;
Vaduganathan, Muthiah .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (08) :2532-2535